Escalating MS drug costs in the US
Puzzling, troubling, and suspicious
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The medical profession and the pharmaceutical industry might seem to have the same motivation: their goals frequently align in health care, and both focus on alleviating the burden of patients' conditions. However, the ethical system of the physician is directed at the best interests of the patient; the ethical system of the pharmaceutical industry is a business ethic, focused on and directed at profit. Keep this in mind as you read Hartung et al.1 as they document the “alarming” escalation of the costs of drugs for patients with multiple sclerosis (MS) in the United States.
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 2185
- © 2015 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Contemporary Issues
The cost of multiple sclerosis drugs in the US and the pharmaceutical industryToo big to fail?Daniel M. Hartung, Dennis N. Bourdette, Sharia M. Ahmed et al.Neurology, April 24, 2015 -
Patient Page
Cost of disease-modifying therapies for multiple sclerosisMurray G. Brown et al.Neurology, May 25, 2015 -
Article
Qualitative study on the price of drugs for multiple sclerosisGaming the systemDaniel M. Hartung, Lindsey Alley, Kirbee A. Johnston et al.Neurology, November 25, 2019 -
Article
Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosisDaniel M. Hartung, Kirbee A. Johnston, Jonah Geddes et al.Neurology, January 15, 2020